170 related articles for article (PubMed ID: 20957443)
1. Monitoring the longitudinal intra-tumor physiological impulse response to VEGFR2 blockade in breast tumors using DCE-CT.
Stantz KM; Cao M; Cao N; Liang Y; Miller KD
Mol Imaging Biol; 2011 Dec; 13(6):1183-95. PubMed ID: 20957443
[TBL] [Abstract][Full Text] [Related]
2. Developing DCE-CT to quantify intra-tumor heterogeneity in breast tumors with differing angiogenic phenotype.
Cao M; Liang Y; Shen C; Miller KD; Stantz KM
IEEE Trans Med Imaging; 2009 Jun; 28(6):861-71. PubMed ID: 19150783
[TBL] [Abstract][Full Text] [Related]
3. Monitoring the effects of anti-angiogenesis on the radiation sensitivity of pancreatic cancer xenografts using dynamic contrast-enhanced computed tomography.
Cao N; Cao M; Chin-Sinex H; Mendonca M; Ko SC; Stantz KM
Int J Radiat Oncol Biol Phys; 2014 Feb; 88(2):412-8. PubMed ID: 24411612
[TBL] [Abstract][Full Text] [Related]
4. Dynamic contrast-enhanced micro-computed tomography correlates with 3-dimensional fluorescence ultramicroscopy in antiangiogenic therapy of breast cancer xenografts.
Pöschinger T; Renner A; Eisa F; Dobosz M; Strobel S; Weber TG; Brauweiler R; Kalender WA; Scheuer W
Invest Radiol; 2014 Jul; 49(7):445-56. PubMed ID: 24598441
[TBL] [Abstract][Full Text] [Related]
5. Dynamic contrast-enhanced magnetic resonance imaging rapidly indicates vessel regression in human squamous cell carcinomas grown in nude mice caused by VEGF receptor 2 blockade with DC101.
Kiessling F; Farhan N; Lichy MP; Vosseler S; Heilmann M; Krix M; Bohlen P; Miller DW; Mueller MM; Semmler W; Fusenig NE; Delorme S
Neoplasia; 2004; 6(3):213-23. PubMed ID: 15153333
[TBL] [Abstract][Full Text] [Related]
6. Nilotinib Enhances Tumor Angiogenesis and Counteracts VEGFR2 Blockade in an Orthotopic Breast Cancer Xenograft Model with Desmoplastic Response.
Zafarnia S; Bzyl-Ibach J; Spivak I; Li Y; Koletnik S; Doleschel D; Rix A; Pochon S; Tardy I; Koyadan S; van Zandvoort M; Palmowski M; Kiessling F; Lederle W
Neoplasia; 2017 Nov; 19(11):896-907. PubMed ID: 28938160
[TBL] [Abstract][Full Text] [Related]
7. Angiogenesis and radiation response modulation after vascular endothelial growth factor receptor-2 (VEGFR2) blockade.
Li J; Huang S; Armstrong EA; Fowler JF; Harari PM
Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1477-85. PubMed ID: 16029810
[TBL] [Abstract][Full Text] [Related]
8. Roles of nitric oxide synthase inhibition and vascular endothelial growth factor receptor-2 inhibition on vascular morphology and function in an in vivo model of pancreatic cancer.
Camp ER; Yang A; Liu W; Fan F; Somcio R; Hicklin DJ; Ellis LM
Clin Cancer Res; 2006 Apr; 12(8):2628-33. PubMed ID: 16638876
[TBL] [Abstract][Full Text] [Related]
9. VEGFR2 heterogeneity and response to anti-angiogenic low dose metronomic cyclophosphamide treatment.
Patten SG; Adamcic U; Lacombe K; Minhas K; Skowronski K; Coomber BL
BMC Cancer; 2010 Dec; 10():683. PubMed ID: 21159176
[TBL] [Abstract][Full Text] [Related]
10. BR55: a lipopeptide-based VEGFR2-targeted ultrasound contrast agent for molecular imaging of angiogenesis.
Pochon S; Tardy I; Bussat P; Bettinger T; Brochot J; von Wronski M; Passantino L; Schneider M
Invest Radiol; 2010 Feb; 45(2):89-95. PubMed ID: 20027118
[TBL] [Abstract][Full Text] [Related]
11. Effect of molecular imaging on validation of developed anti-hVEGFR2 therapeutic antibody.
Cheong SJ; Lee CM; Jang D; Kim EM; Jeong MH; Uhm TB; Lee WS; Jeong HJ; Kim DW; Lim ST; Sohn MH
Cancer Biother Radiopharm; 2011 Dec; 26(6):745-51. PubMed ID: 22003972
[TBL] [Abstract][Full Text] [Related]
12. VEGFR2-Targeted Contrast-Enhanced Ultrasound to Distinguish between Two Anti-Angiogenic Treatments.
Payen T; Dizeux A; Baldini C; Le Guillou-Buffello D; Lamuraglia M; Comperat E; Lucidarme O; Bridal SL
Ultrasound Med Biol; 2015 Aug; 41(8):2202-11. PubMed ID: 25980323
[TBL] [Abstract][Full Text] [Related]
13. Detecting vascular changes in tumour xenografts using micro-ultrasound and micro-ct following treatment with VEGFR-2 blocking antibodies.
Cheung AM; Brown AS; Cucevic V; Roy M; Needles A; Yang V; Hicklin DJ; Kerbel RS; Foster FS
Ultrasound Med Biol; 2007 Aug; 33(8):1259-68. PubMed ID: 17467156
[TBL] [Abstract][Full Text] [Related]
14. Targeted anti-vascular endothelial growth factor receptor-2 therapy leads to short-term and long-term impairment of vascular function and increase in tumor hypoxia.
Franco M; Man S; Chen L; Emmenegger U; Shaked Y; Cheung AM; Brown AS; Hicklin DJ; Foster FS; Kerbel RS
Cancer Res; 2006 Apr; 66(7):3639-48. PubMed ID: 16585189
[TBL] [Abstract][Full Text] [Related]
15. Synergistic antitumor effects of combined epidermal growth factor receptor and vascular endothelial growth factor receptor-2 targeted therapy.
Tonra JR; Deevi DS; Corcoran E; Li H; Wang S; Carrick FE; Hicklin DJ
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2197-207. PubMed ID: 16609035
[TBL] [Abstract][Full Text] [Related]
16. YM-359445, an orally bioavailable vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor, has highly potent antitumor activity against established tumors.
Amino N; Ideyama Y; Yamano M; Kuromitsu S; Tajinda K; Samizu K; Hisamichi H; Matsuhisa A; Shirasuna K; Kudoh M; Shibasaki M
Clin Cancer Res; 2006 Mar; 12(5):1630-8. PubMed ID: 16533791
[TBL] [Abstract][Full Text] [Related]
17. Anti-vascular effects of the cytosolic phospholipase A2 inhibitor AVX235 in a patient-derived basal-like breast cancer model.
Kim E; Tunset HM; Cebulla J; Vettukattil R; Helgesen H; Feuerherm AJ; Engebråten O; Mælandsmo GM; Johansen B; Moestue SA
BMC Cancer; 2016 Mar; 16():191. PubMed ID: 26951085
[TBL] [Abstract][Full Text] [Related]
18. Contrast-Enhanced Ultrasound with VEGFR2-Targeted Microbubbles for Monitoring Regorafenib Therapy Effects in Experimental Colorectal Adenocarcinomas in Rats with DCE-MRI and Immunohistochemical Validation.
Eschbach RS; Clevert DA; Hirner-Eppeneder H; Ingrisch M; Moser M; Schuster J; Tadros D; Schneider M; Kazmierczak PM; Reiser M; Cyran CC
PLoS One; 2017; 12(1):e0169323. PubMed ID: 28060884
[TBL] [Abstract][Full Text] [Related]
19. Apatinib, a selective VEGFR2 inhibitor, improves the delivery of chemotherapeutic agents to tumors by normalizing tumor vessels in LoVo colon cancer xenograft mice.
Zhou K; Zhang JW; Wang QZ; Liu WY; Liu JL; Yao L; Cai MM; Ni SY; Cai QY; Wang GJ; Zhou F
Acta Pharmacol Sin; 2019 Apr; 40(4):556-562. PubMed ID: 29977004
[TBL] [Abstract][Full Text] [Related]
20. Prioritization of EGFR/IGF-IR/VEGFR2 combination targeted therapies utilizing cancer models.
Tonra JR; Corcoran E; Deevi DS; Steiner P; Kearney J; Li H; Ludwig DL; Zhu Z; Witte L; Surguladze D; Hicklin DJ
Anticancer Res; 2009 Jun; 29(6):1999-2007. PubMed ID: 19528458
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
